Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Raltitrexed in mCRC
NCT06118762Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by First Affiliated Hospital of Nanchang University. Started Oct 2023; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06118762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118762.